Insider trust linked to IRADIMED (NASDAQ: IRMD) sells 7,500 shares
Rhea-AI Filing Summary
IRADIMED CORP director and CEO Roger E. Susi reported indirect open-market sales of company common stock through the Phillip Susi 2008 Dynasty Trust. On March 16–17, 2026, the trust sold a total of 7,500 shares at weighted average prices of about $101.18, $101.68 and $102.43 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025, indicating they were scheduled in advance. After these transactions, the Phillip Susi 2008 Dynasty Trust holds 2,240,000 shares. The filing also lists additional indirect holdings of 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, with Susi disclaiming beneficial ownership beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Pre-planned, small insider sales with large indirect stake remaining.
The filing shows open-market sales of 7,500 IRADIMED CORP shares by the Phillip Susi 2008 Dynasty Trust at prices around $101–$102. These were executed under a Rule 10b5-1 plan, which is typically established in advance to automate trading.
After these transactions, the trust still holds 2,240,000 shares, and other trusts collectively hold hundreds of thousands more. Relative to these indirect positions, the sale size appears small, suggesting a routine liquidity or diversification pattern rather than a major change in exposure. Susi also formally disclaims beneficial ownership beyond his pecuniary interest, emphasizing that the shares are held in trust structures.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,500 | $102.43 | $256K |
| Sale | Common Stock | 3,009 | $101.18 | $304K |
| Sale | Common Stock | 1,991 | $101.68 | $202K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025. This transaction was executed in multiple trades at prices ranging from $100.37 to $101.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $101.38 to $101.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $102.06 to $102.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
